Barclays Maintains Overweight on BeOne Medicines, Raises Price Target to $409

Benzinga Newsdesk www.benzinga.com Positive 81.4%

Neg 0% Neu 0% Pos 81.4%

Barclays analyst Peter Lawson maintains BeOne Medicines (NASDAQ:ONC) with a Overweight and raises the price target from $405 to $409.